Top Biotechnology Stocks To Buy In 2022 – Best Stocks

The biotech sector is one of the most dynamic and unpredictable industries. While some companies struggle to stay afloat, others thrive with the help of intelligent management and timely product launches. Biotech stocks are volatile, but these companies offer lucrative investment opportunities if you know where to look. Keep reading to learn more about the biotech sector and our top picks for 2022. Our list will help you find the best stocks to invest in now and in the future, no matter how volatile this sector becomes. These markets have proven growth potential due to their current size or recent expansion efforts. Each company on this list offers value as a long-term holding regardless of market fluctuations.

Avidity Biosciences is a clinical-stage biopharmaceutical company focused on developing RNA-based therapeutics. The companys lead candidate is CADATE-19, a potent antisense oligonucleotide, or ASO, designed to treat hypercholesterolemia. CADATE-19 has completed a Phase III clinical trial, and Avidity plans to submit a Neplannedg Application in 2021. If approved, CADATE-19 could capture a large share of the hypercholesterolemia treatment market, where the current market leader has an 80% share. The company also has a preclinical drug for Huntingtons disease. This rare genetic disorder causes nerve and muscle degeneration, leading to cognitive impairment, mood changes, and death. Overall, Avidity Biosciences has a strong product pipeline for treating several rare diseases, including hypercholesterolemia, hemophilia, and Huntingtons. In addition, the company has a good chance of success, given that its lead products have already completed Phase III clinical trials.

Syndax Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing drugs to treat rare diseases. The companys lead product is Texas, an intravenous treatment for patients with hereditary ATTR amyloidosis, an incurable, degenerative muscle disease that often leads to heart failure. Texas is currently in Phase III clinical trial. If approved, the drug will be reserved only for patients with ATTR amyloidosis who have already undergone a liver transplant. Syndax PharmaceuticalIn addition, s is also developing SD-101, a treatment intended to treat hereditary ATTR amyloidosis. If approved, SD-101 could capture a large share of the genetic ATTR amyloidosis treatment market, which is currently under $1 billion. Overall, Syndax Pharmaceuticals is a strong company with a good chance of success with its lead products. Although hereditary ATTR amyloidosis is a rare disease, the number of patients with this condition is expected to grow.

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering and developing drugs based on RNA interference, or RNAi. The companys lead product is S1AL19, a treatment for patients with familial amyloidosis, a rare genetic disorder that causes the buildup of a protein called amyloid in the organs and tissues. S1AL19 is currently in Phase III clinical trial. If approved, the drug could capture a large share of the familial amyloidosis treatment market, which is currently worth $1 billion annually. In addition, the company also has a preclinical cure for hereditary ATTR amyloidosis, a rare genetic disorder affecting the heart and kidneys. Overall, Alnylam Pharmaceuticals is a strong company with a good chance of success with its two lead products. Familial amyloidosis is a rare disease, but the number of patients with this condition is expected to grow.

Travel Therapeutics Holdings is a biopharmaceutical company focused on developing therapies for neurological diseases. The companys lead product candidate is CT1819, an intravenous treatment for patients with hereditary ATTR amyloidosis. Travel Therapeutics drug is currently in Phase II/III clinical trial. If approved, CT1819 could capture a large share of the genetic ATTR amyloidosis treatment market, which is currently worth $1 billion annually. The company also has, In addition, there clinical drug candidates for familial amyloidosis. Overall, Cerevel Therapeutics Holdings is a strong company with a good chance of success with its two lead products. Like hereditary ATTR amyloidosis, familial amyloidosis is a rare disease, but the number of patients with this condition is expected to grow.

Biotech stocks are notoriously volatile, and its important to remember that a single good or bad day can wipe out months of progress. That being said, the top biotech stocks for 2022 are poised for significant gains over the long term. These companies have various innovative products in their pipelines, from RNA-based therapeutics to RNAi-based drugs. With support from stakeholders and the market, these biotech stocks could dramatically outperform the broader market in 2022 and beyond.

Excerpt from:
Top Biotechnology Stocks To Buy In 2022 - Best Stocks